Publications

Year	Title/Author
2023	Immunoaffinity LC-MS/MS Quantification of the Sepsis Biomarker Procalcitonin Using Magnetic- and Polystyrene-Bead Immobilized Polyclonal Antibodies Tölke S, Masetto T, Reuschel T, Grimmler M, Bindila L, Schneider K
2023	Comprehensive Comparison of the Capacity of Functionalized Sepharose, Magnetic Core, and Polystyrene Nanoparticles to Immuno-Precipitate Procalcitonin from Human Material for the Subsequent Quantification by LC-MS/MS. Masetto T, Matzenbach K, Reuschel T, Tölke SA, Schneider K, Esser LM, Reinhart M, Bindila L, Peter C, Grimmler M
2022	National external quality assessment and direct method comparison reflect crucial deviations of Procalcitonin measurements in Germany. Masetto T, Eidizadeh A, Peter C, Grimmler M.
2021	Letter to the Editor regarding “Development of an antibody-free ID-LC MS method for the quantification of procalcitonin in human serum at sub-microgram per liter level using a peptide-based calibration”. Tölke SA, Masetto T, Grimmler M, Bindila L, Schneider K.
2021	Evaluation of the necessity and the feasibility of the standardization of procalcitonin measurements: Activities of IFCC WG-PCT with involvement of all stakeholders. Huynh HH, Bœuf A, Vinh J, Delatour V; IFCC Working Group on Standardization of Procalcitonin assays (WG-PCT).
2020	Bioanalytical Performance of a New Particle-Enhanced Method for Measuring Procalcitonin Dupuy AM, Bargnoux AS, Larcher R, Merindol A, Masetto T, Badiou S, Cristol JP

An All-Purpose Particle Enhanced Immunoturbidimetric Assay for the Comparable, Instrument-Independent Monitoring of Procalcitonin in the Management of Sepsis

Procalcitonin (PCT) revealed to be an indispensable parameter for the management of sepsis. However, recent analysis of EQA survey results suggested crucial deviations of PCT measurements in Germany and studies by the IFCC Working Group on standardization of PCT stated the need for a higher-order reference measurement procedure. Here we present the evaluation of the all-purpose particle enhanced immunoturbidimetric assay (PETIA) of DiaSys, which can be easily applied to every high-throughput clinical chemistry analyzer. The high diversity of applications and datasets match current diagnostic and regulatory needs (IVDR). In addition, the high comparability between the seven analyzers enables the reliable and instrument-independent monitoring of PCT in the management of sepsis, thus offering a solution to the current landscape of deviating PCT measurement results.

Download poster

Evaluation of a new accurate and reliable particle enhanced immunoturbidimetric assay for the detection of Procalcitonin in the management of sepsis

The Third International Consensus Definitions for Sepsis and Septic Shock redefined sepsis as the life-threatening organ dysfunction caused by a dysregulated host response to infection. Sepsis is considered as a major public healthcare issue affecting more than 30 million people worldwide, associated with a mortality of potentially 6 million people and accounts for almost $24 billion in health care expenditures only in the US, annually. As the quick and accurate sepsis management reduces a possible negative clinical course and the economic burden, a multiplicity of plasma biomarker have been developed to overcome the long turn-around time of the blood culture. [...]

Download

Procalcitonin FS

The reliable alternative, when time matters

Publications